The future of oncology policy

Gill, Jennifer L, Mills, Mackenzie J, Wharton, George A ORCID: 0000-0001-6544-3636 and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2022) The future of oncology policy. Journal of Cancer Policy, 34. ISSN 2213-5383

Text (1-s2.0-S2213538322000315-main) - Published Version Available under License Creative Commons Attribution. Download (354kB)

• Author
• Author
• Scopus publication

Abstract

To ensure the previous progress seen in cancer survival rates continues as we move through the 21st Century it is important to determine future effective policy related to oncology healthcare delivery and funding. Recent successes with, for example, the COVID vaccine response, the decision-making agility exhibited by governments and healthcare systems and the effective use of telehealth and real-world evidence highlight the progress that can be made with pooled efforts and innovative thinking. This shared approach is the basis for the European Beating Cancer Plan which outlines action points for governments and health systems for the period 2021-2025. It focuses on a whole government approach, centred on patients, maximising the potential of new technologies and insights across policy areas including employment, education, transport and taxation, enabling the tackling of cancer drivers in schools, workplaces, research labs, towns and cities and rural communities. Despite the plan there are still concerns that oncology policy has not adequately responded to the pace of innovation and the unique challenges generated by innovative oncological technologies. There needs to be focus on: gaining consensus on the most appropriate methods to assess and price combination therapies and cell and gene therapies, developing effective outcome-based payment models for personalised medicine and developing consensus on the ideal approach for multiple indication pricing. Finally, future policy needs to ensure pharmaceutical companies and other research organisations are adequately rewarded for innovation to ensure continued R&D and the development of innovative oncological products.

Item Type:	Article
Official URL:	https://www.sciencedirect.com/journal/journal-of-c...
Additional Information:	© 2022 The Authors
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	11 Aug 2022 09:30
Last Modified:	12 Dec 2024 03:12
URI:	http://eprints.lse.ac.uk/id/eprint/115965

Actions (login required)

View Item